Patent for Radiation Dose Enhancement and Tumor Delineation

The United States Patent and Trademark Office (USPTO) has published a new patent application, US20260083850A1, detailing agents and methods for radiation dose enhancement and tumor delineation. The application, filed by the University of Connecticut, specifically describes the use of barium nanoparticles, such as BaTiO3, to improve the efficacy of megavoltage radiation therapy and to aid in the delineation of tumors. This represents a new disclosure of potential therapeutic technology.

This patent application does not impose any immediate compliance obligations on regulated entities. However, companies involved in pharmaceutical development, medical device manufacturing, or cancer treatment technologies should monitor this patent for potential future licensing opportunities or competitive intelligence. The filing date was September 24, 2025, with publication scheduled for March 26, 2026.